Business Context and Reporting Period
This Form 8-K is filed by Renovaro Inc. (NASDAQ: RENB) with a report date of January 1, 2025, covering events occurring on January 6, 2025. The filing discloses the entry into a binding letter of intent to acquire Predictive Oncology Inc. (NASDAQ: POAI). Note: The request metadata references "Lunai Bioworks Inc.," but the filing text explicitly identifies the registrant as Renovaro Inc.
Key Financial Metrics and Transaction Terms
The filing details a proposed acquisition structure rather than standard operating financial metrics. Key transaction terms include:
- Exchange Ratio: Predictive Oncology shareholders will receive a newly created series of Renovaro preferred stock in a 1:1 exchange for their existing common stock.
- Redemption Value: The preferred stock is automatically redeemable for $3.00 per share after 18 months.
- Conversion Trigger: Preferred stock may convert to Renovaro common stock at a 1:1 ratio if Renovaro's common stock trades at or above $4.50 per share for 30 consecutive trading days.
- Warrant Buyback: Renovaro agreed to purchase up to 2.33 million shares of Predictive Oncology common stock at $1.07 per share if Series A and Series B warrants are not exercised by January 15, 2025.
- Fundraising Condition: The merger is contingent upon Renovaro raising a minimum of $15 million.
The filing text does not provide clear values for Renovaro's current revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Contingencies
The primary material change is the potential acquisition of Predictive Oncology. The transaction is subject to several contingencies:
- Execution of definitive documentation by no later than February 28, 2025.
- Completion of a minimum $15 million fundraising by Renovaro.
- Formal approval by Predictive Oncology shareholders.
- Alternative Outcome: If shareholder approval is not obtained within 60 days of the definitive agreement (and specific capital conditions are met), Renovaro is entitled to a two-year exclusive, royalty-free license to Predictive Oncology's biobank of tumor samples and tumor-specific 3D cell culture models.
Guidance, Outlook, and Risks
Management has stated there can be no assurance that a definitive merger agreement will be executed or regarding the timing of such a transaction. Renovaro does not intend to disclose further developments unless the Board of Directors approves a transaction or disclosure is required by law. The filing incorporates a press release as Exhibit 99.1 but explicitly states that the exhibit and information are "furnished" and not "filed" for Regulation FD purposes.
Investor Verification Checklist
- Verify the successful completion of the required $15 million fundraising by Renovaro.
- Confirm the execution of the definitive merger agreement by the February 28, 2025 deadline.
- Monitor the status of Predictive Oncology Series A and Series B warrant exercises prior to January 15, 2025.
- Track Renovaro's common stock price to assess the likelihood of the $4.50 conversion trigger.
- Review the outcome of the Predictive Oncology shareholder vote on the merger.